Updates are available Correction dated 2023-01-20
Click to view Correction: https://doi.org/10.1007/s10388-023-00986-1
-
Authors
Mitani, Seiichiro
Kawakami, Hisato https://orcid.org/0000-0002-3280-4850
Shiraishi, Osamu
Kanemura, Hiroaki
Suzuki, Shinichiro
Haratani, Koji
Hayashi, Hidetoshi
Yonesaka, Kimio
Chiba, Yasutaka
Yasuda, Takushi
Nakagawa, Kazuhiko
-
Funding
Funding for this research was provided by:
2022 Kindai University Research Enhancement Grant (SR17)
- License Information
-
More Information
Article History
Received: 26 September 2022
Accepted: 28 November 2022
First Online: 9 December 2022
Change Date: 20 January 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10388-023-00986-1
Declarations
:
: This study was approved by the institutional review boards of Kindai University (number: 31–234).
: Seiichiro Mitani reports grants from Taiho Pharmaceutical Co., payment or honoraria from Taiho Pharmaceutical Co., and participation on advisory board of Chugai Pharmaceutical Co. Ltd. Hisato Kawakami reports consulting fees from Daiichi-Sankyo Co. Ltd.; honoraria from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co., Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd., Incyte Biosciences Japan., Yakult Pharmaceutical Industry., and Taiho Pharmaceutical Co. Ltd.; lecture fees from Glaxo Smith Kline K.K., and Otsuka Pharmaceutical Co., Ltd.; and research funding from Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd, Kobayashi Pharmaceutical. Co., Ltd., and Eisai Co. Ltd. Koji Haratani reports grants from AstraZeneca K.K. and MSD K.K. and payment or honoraria from AS ONE Corporation, Bristol-Myers Squibb Co. Ltd., MSD K.K., and Ono Pharmaceutical Co. Ltd. Kimio Yonesaka reports grants from Daiichi Sankyo Co., Ltd. and payment or honoraria from Chugai Pharmaceutical Co. Ltd., AstraZeneca K.K., Eli Lilly Japan K.K., Takeda Pharmaceutical Co. Ltd., MSD K.K., and Nippon Kayaku. Hayashi reports grants from Chugai Pharmaceutical Co. Ltd., AstraZeneca K.K., Astellas Pharma Inc., Merck Sharp & Dohme K.K., Ono Pharmaceutical Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Pfizer Japan Inc., Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., Daiichi-Sankyo Co. Ltd., Merck Serono Co. Ltd./Merck Biopharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., SymBio Pharmaceuticals Limited, AbbVie Inc., inVentiv Health Japan, ICON Japan K.K., Gritstone Oncology Inc., Parexel International Corp., Kissei Pharmaceutical Co. Ltd., EPS Corporation, Syneos Health, Pfizer R&D Japan G.K., A2 Healthcare Corp., Quintiles Inc./IQVIA Services Japan K.K., EP-CRSU Co. Ltd., Linical Co. Ltd., Eisai Co. Ltd., CMIC Shift Zero K.K., Kyowa Hakko Kirin Co. Ltd., Bayer Yakuhin Ltd., EPS International Co. Ltd., and Otsuka Pharmaceutical Co. Ltd., payment or honoraria from AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Kyorin Pharmaceutical Co. Ltd., Merck Biopharma Co. Ltd., Merck Sharp & Dohme K.K., Novartis Pharmaceuticals K.K., Ono Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co. Ltd., and consulting fees from AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., Shanghai Haihe Biopharma, Takeda Pharmaceutical Co. Ltd., and Merck Biopharma Co. Ltd. Kazuhiko Nakagawa reports grants from MSD K.K., Daiichi Sankyo Co. Ltd., Taiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., AstraZeneca K.K., SymBio Pharmaceuticals Limited., Novartis Pharma K.K., IQVIA Services JAPAN K.K., Covance Japan Inc. AbbVie Inc., Medical Research Support, Nippon Boehringer Ingelheim Co. Ltd., SYNEOS HEALTH CLINICAL K.K., Pfizer R & D Japan G.K., Eisai Co. Ltd. Takeda Pharmaceutical Co. Ltd., Sanofi K.K., EPS Corporation, Pfizer Japan Inc. Sysmex Corporation, Ono Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Bristol Myers Squibb Company, A2 Healthcare Corp., PAREXEL International Corp., Japan Clinical Research Operations, GlaxoSmithKline K.K., and payment or honoraria from Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., KYORIN Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Pfizer Japan Inc., MSD K.K., Merck Biopharma Co. Ltd. All remaining authors declare no conflicts of interest.
: The data will be made available, on reasonable request, starting from the time of publication.
